Skip to main content

MoneyWorks4Me

Zydus Lifesciences informs about press release

25 Oct 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 25, 2023 titled ‘Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)’.

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1896.00
Dr. Reddys Labs. 1376.00
Cipla 1417.00
Lupin 2021.00
Zydus Lifesciences 1190.10
View more..